Leptospirosis in Dogs: Clinical Signs, Diagnosis, and Zoonotic Risk Management

Abstract

Canine leptospirosis represents a globally distributed zoonotic bacterial disease caused by pathogenic spirochetes of the genus Leptospira. The disease manifests with heterogeneous clinical presentations ranging from subclinical infection to acute kidney injury, hepatic dysfunction, pulmonary hemorrhage, and multi-organ failure. This review synthesizes current knowledge regarding the etiology, pathogenesis, clinical manifestations, diagnostic modalities, vaccination strategies, and zoonotic risk management frameworks essential for veterinary practitioners and diagnostic laboratories. Emphasis is placed on the integration of serological and molecular diagnostics, interpretation of microscopic agglutination test (MAT) titers in vaccinated populations, and implementation of biosecurity protocols aligned with One Health principles.

1. Introduction and Etiology

Leptospira species are obligate aerobic spirochetes characterized by helical morphology, axial flagella enabling corkscrew motility, and a double-membrane architecture resembling Gram-negative bacteria. The genus comprises over 300 pathogenic serovars classified into serogroups based on antigenic relatedness of the lipopolysaccharide (LPS) component. In dogs, the most frequently implicated serovars include Canicola, Icterohaemorrhagiae, Grippotyphosa, Pomona, Bratislava, and Autumnalis, though geographic variation in serovar prevalence is substantial [3, 6, 11, 13].

Transmission occurs through direct contact with infected urine or indirect exposure to contaminated water, soil, or fomites. The organism penetrates intact mucous membranes or abraded skin, enters the bloodstream (leptospiremia), and disseminates to target organs including kidneys, liver, lungs, and reproductive tract. Renal tubular colonization establishes a carrier state with intermittent urinary shedding, perpetuating environmental contamination [8, 9].

Recent genomic analyses reveal high nucleotide identity among Leptospira interrogans isolates from dogs, humans, and wildlife within shared ecosystems, supporting cross-species transmission dynamics [10]. Molecular surveillance in urban and peri-urban settings has identified novel sequence types and evidence of recombination events, underscoring the need for ongoing genomic epidemiology [3, 11].

2. Pathogenesis and Host-Pathogen Interactions

2.1 Virulence Mechanisms

Pathogenic Leptospira express surface-exposed proteins facilitating host adhesion, immune evasion, and tissue invasion. Key virulence factors include:

• LipL32: Major outer membrane protein mediating binding to extracellular matrix components (collagen IV, laminin, fibronectin)
• Loa22: OmpA-like protein essential for virulence, expressed during mammalian infection
• LigA/LigB: Immunoglobulin-like repeat proteins binding fibrinogen, complement regulators, and elastin
• SphH: Sphingomyelinase hemolysin contributing to endothelial damage and vascular permeability

The LPS of pathogenic Leptospira exhibits low endotoxic activity compared to classical Gram-negative pathogens, potentially delaying innate immune recognition. However, TLR2 and TLR4 signaling pathways are activated, triggering pro-inflammatory cytokine cascades (TNF-α, IL-6, IL-1β) that contribute to tissue injury [4, 12].

2.2 Renal Pathophysiology

The kidney represents the primary target organ and reservoir for persistent infection. Leptospires colonize the proximal tubular epithelium and interstitial spaces, inducing tubulointerstitial nephritis characterized by:

• Tubular epithelial necrosis and desquamation
• Interstitial infiltration by macrophages, lymphocytes, and plasma cells
• Fibrosis and tubular atrophy in chronic phases
• Impaired concentrating ability and electrolyte transport

Acute kidney injury (AKI) develops through combined ischemic, toxic, and immune-mediated mechanisms. Reduced renal perfusion secondary to vasculitis and hypovolemia compounds direct tubular toxicity. Serum symmetric dimethylarginine (SDMA) and creatinine elevations typically precede oliguria or anuria [1, 4].

2.3 Hepatic Pathophysiology

Hepatic involvement manifests as centrilobular necrosis, cholestasis, and hepatocellular dysfunction. Leptospires localize in the space of Disse and Kupffer cells, disrupting bile canaliculi integrity. Clinical jaundice results from conjugated hyperbilirubinemia secondary to impaired hepatocellular excretion and intrahepatic cholestasis. Serum alanine aminotransferase (ALT) and alkaline phosphatase (ALP) elevations are common, though typically less pronounced than in primary hepatic diseases [3, 13].

2.4 Pulmonary Manifestations

Pulmonary hemorrhage syndrome represents a severe, often fatal complication. Pathogenesis involves endothelial injury, capillary leakage, and alveolar hemorrhage driven by leptospiral toxins and host inflammatory mediators. Serial imaging studies document progressive ground-glass opacities, consolidation, and pleural effusion correlating with clinical deterioration [1]. Thrombocytopenia and coagulopathy exacerbate hemorrhagic diathesis.

3. Clinical Signs and Syndrome Classification

3.1 Acute Presentation

The incubation period ranges from 4 to 12 days. Clinical signs reflect multi-organ involvement and vary by serovar virulence, host immune status, and infectious dose.

Table 1: Clinical Manifestations of Canine Leptospirosis by Organ System

3.2 Subclinical and Chronic Presentations

Subclinical infections are common, particularly with serovars Bratislava and Autumnalis. These dogs serve as maintenance hosts, shedding organisms intermittently in urine for months to years. Chronic kidney disease (CKD) may develop following acute infection, characterized by progressive fibrosis and loss of functional nephrons. Serological monitoring of recovered dogs reveals persistent MAT titers that complicate interpretation of subsequent exposures [8, 15].

3.3 Uncommon Manifestations

Ocular involvement including uveitis, keratitis, and optic neuritis has been documented. A pilot study investigating Leptospira as a cause of endogenous uveitis in cats identified serological evidence of exposure, suggesting potential cross-species ocular tropism [14]. Reproductive failure manifesting as abortion, stillbirth, or weak neonates occurs in pregnant bitches infected during gestation.

4. Diagnostic Approaches

4.1 Diagnostic Algorithm

A tiered diagnostic strategy integrating clinical suspicion, serology, and molecular detection optimizes sensitivity and specificity across disease stages.

flowchart TD
    A[Clinical Suspicion: Acute febrile illness, AKI, hepatic dysfunction, pulmonary hemorrhage], > B{Acute Phase < 7 days?}
    B, >|Yes| C[PCR on Blood/Urine]
    B, >|No| D[MAT Acute Titer]
    C, > E{PCR Positive?}
    E, >|Yes| F[Confirmatory Diagnosis]
    E, >|No| G[Repeat PCR in 48h + MAT Acute/Convalescent]
    D, > H{MAT Titer >= 1:800?}
    H, >|Yes| I[Supportive Evidence]
    H, >|No| J[Convalescent MAT 2-4 weeks]
    J, > K{4-fold Titer Rise?}
    K, >|Yes| F
    K, >|No| L[Consider Alternative Diagnoses]
    G, > K
    I, > M[Paired Titers for Confirmation]
    M, > K
    F, > N[Treatment Initiation + Zoonotic Precautions]
    L, > O[Monitor Clinical Course]

4.2 Microscopic Agglutination Test (MAT)

The MAT remains the reference standard for serological diagnosis. Live Leptospira antigens representing locally prevalent serovars are incubated with serial serum dilutions. The endpoint titer represents the highest dilution yielding 50% agglutination.

Interpretation Guidelines:

• Acute infection: Single titer ≥ 1:800 with compatible clinical signs
• Confirmed infection: Four-fold rise in paired acute/convalescent titers (2-4 week interval)
• Vaccination interference: Vaccinal titers typically ≤ 1:1600, decline within 3-6 months; however, recent multivalent vaccines may induce titers ≥ 1:3200 to included serovars
• Cross-reactivity: Significant cross-agglutination occurs among serovars within serogroups; the infecting serovar is inferred from the highest titer

Limitations include requirement for live antigen maintenance, subjective endpoint determination, inability to distinguish infection from vaccination without paired sera, and reduced sensitivity in early acute phase (< 7 days) [3, 6, 13].

4.3 Polymerase Chain Reaction (PCR)

Molecular detection of Leptospira DNA in blood (early acute) or urine (later acute/convalescent) provides rapid, specific diagnosis. Target genes include lipL32, 16S rRNA, secY, and gyrB. Quantitative PCR (qPCR) enables bacterial load quantification, correlating with disease severity and shedding intensity.

Sample Selection and Timing:

• Blood/Serum: Days 0-10 post-infection (leptospiremic phase)
• Urine: Days 7-14 onward (renal shedding phase); centrifugation improves yield
• Tissues: Kidney, liver, lung at necropsy

Advantages: Unaffected by vaccination, high specificity, rapid turnaround, quantitative capability. Limitations: Intermittent urinary shedding causes false negatives; antibiotic administration prior to sampling reduces sensitivity; does not identify infecting serovar [3, 11, 13].

4.4 Emerging Diagnostic Technologies

4.4.1 Recombinant Antigen-Based Assays

A lateral flow assay utilizing recombinant Loa22 protein conjugated to gold nanoparticles demonstrates promising sensitivity and specificity for canine and bovine serodiagnosis [12]. This point-of-care format detects anti-Loa22 IgG, which is expressed during mammalian infection but absent in vaccine preparations (typically whole-cell bacterins). Field validation across diverse geographic regions is ongoing.

4.4.2 Biomarker Discovery

Serum sialic acid, an acute-phase reactant reflecting glycosylation changes in inflammatory glycoproteins, shows elevation in canine leptospirosis and correlates with disease severity [4]. Integration of sialic acid with traditional markers (creatinine, bilirubin, CRP) may enhance diagnostic algorithms and prognostic stratification.

4.4.3 Next-Generation Sequencing

Metagenomic and targeted amplicon sequencing enable direct characterization of Leptospira populations in clinical specimens without culture. Applications include serovar identification, antimicrobial resistance profiling, and transmission chain reconstruction [10, 11].

4.5 Differential Diagnosis

Table 2: Key Differential Diagnoses for Canine Leptospirosis

5. Vaccination Protocols

5.1 Vaccine Composition and Immunogenicity

Commercial canine leptospirosis vaccines are inactivated whole-cell bacterins adjuvanted with aluminum hydroxide or oil-in-water emulsions. Traditional bivalent vaccines contain serovars Canicola and Icterohaemorrhagiae. Quadrivalent formulations incorporate Grippotyphosa and Pomona, addressing emerging serovar shifts documented in multiple regions [6, 9, 13, 15].

Immunity is primarily humoral, mediated by anti-LPS antibodies providing serovar-specific protection. Cell-mediated immunity contributes to clearance of established infection. Duration of immunity (DOI) studies support annual revaccination, though challenge studies demonstrate protection persisting 12-15 months for homologous serovars.

5.2 Vaccination Schedule

Primary Series:

• Initial dose: 8-9 weeks of age
• Second dose: 3-4 weeks later (12-13 weeks)
• Third dose (optional, high-risk areas): 16 weeks

Revaccination:

• Annual booster with quadrivalent vaccine
• Semi-annual consideration for dogs in endemic zones with high environmental exposure (working dogs, hunting dogs, urban rodents)

5.3 Vaccine Efficacy and Limitations

Vaccines reduce clinical disease severity and renal shedding but may not prevent infection or colonization entirely. Breakthrough infections with non-vaccine serovars occur. Maternal antibody interference necessitates completion of primary series after 12 weeks. Adverse events include transient lethargy, local swelling, and rare Type I hypersensitivity reactions (estimated < 0.5% of doses) [3, 6, 13].

5.4 Serological Monitoring Post-Vaccination

MAT titers post-vaccination peak at 2-4 weeks and decline exponentially. Interpretation of diagnostic MAT in vaccinated dogs requires:

• Knowledge of vaccine serovars and timing
• Paired titers demonstrating four-fold rise
• PCR confirmation of active infection
• Consideration of Loa22-based assays unaffected by vaccinal antibodies [12]

6. Zoonotic Risk Management and One Health Framework

6.1 Transmission Risk Assessment

Dogs with acute leptospirosis shed 10^4-10^7 organisms/mL urine during the leptospiruric phase. Human infection occurs through direct contact with infected urine, contaminated environments, or aerosolized droplets. Veterinary personnel, owners, and household contacts represent at-risk populations. A study evaluating infection risk in dogs contacting clinical cases demonstrated elevated seroconversion rates in co-housed animals, confirming horizontal transmission potential [8].

Environmental persistence is enhanced by neutral to alkaline pH, temperatures 15-30°C, and moisture. Meteorological factors including rainfall, flooding, and temperature extremes correlate with seasonal incidence peaks in both canine and human populations [2, 5].

6.2 Biosecurity Protocols for Veterinary Facilities

Table 3: Infection Control Measures for Hospitalized Leptospirosis Patients

6.3 Owner Safety and Public Health Communication

Owners of diagnosed dogs should receive:

• Verbal and written zoonotic risk explanation
• Guidance on urine cleanup (gloves, bleach solution, hand hygiene)
• Recommendation for household member medical evaluation if febrile illness develops within 3 weeks
• Notification of local public health authorities per reportable disease regulations
• Environmental risk assessment (standing water, rodent control, wildlife access)

6.4 One Health Surveillance Integration

Integrated surveillance linking veterinary diagnostic laboratories, public health agencies, and environmental monitoring enhances outbreak detection. Data sharing platforms enabling real-time mapping of canine cases, human cases, and environmental Leptospira detection support targeted interventions [2, 5, 7]. Genomic epidemiology connecting canine, human, and wildlife isolates elucidates transmission networks and informs vaccine strain selection [10, 11].

7. Therapeutic Management

7.1 Antimicrobial Therapy

Doxycycline: 5 mg/kg PO q12h for 14 days (drug of choice for leptospiremic and leptospiruric phases). Excellent tissue penetration, including renal tubular secretion. Administer with food to reduce gastrointestinal irritation.

Penicillin Derivatives: Ampicillin 20 mg/kg IV q6h or penicillin G 20,000-40,000 IU/kg IV q6h for initial bacteremia control (first 3-5 days), followed by doxycycline completion. Penicillins do not eliminate renal carriage.

Alternative Agents: Ceftriaxone, azithromycin, or fluoroquinolones for doxycycline-intolerant patients.

7.2 Supportive Care

• Fluid Therapy: Balanced crystalloids with potassium supplementation; avoid overhydration in oliguric patients
• Renal Replacement Therapy: Hemodialysis or peritoneal dialysis for severe AKI with volume overload, refractory electrolyte disturbances, or uremic complications
• Gastroprotection: Antiemetics (maropitant, ondansetron), H2 blockers or proton pump inhibitors
• Nutritional Support: Enteral feeding via nasoesophageal tube if anorexia > 48 hours
• Blood Products: Fresh frozen plasma for coagulopathy; packed red blood cells for severe anemia

7.3 Prognostic Indicators

Negative prognostic factors include oliguric/anuric AKI requiring dialysis, pulmonary hemorrhage syndrome, severe thrombocytopenia (< 50 × 10^9/L), and multi-organ dysfunction syndrome (MODS). Survival to discharge ranges 70-85% with aggressive management; dialysis-dependent patients have 50-60% survival [1, 3].

8. Epidemiological Trends and Geographic Distribution

8.1 Global Serovar Dynamics

Serovar prevalence exhibits marked geographic and temporal variation. In North America, Grippotyphosa and Pomona have increased relative to traditional Canicola/Icterohaemorrhagiae [3, 6]. European surveillance identifies Bratislava (maintained by hedgehogs and rodents) and Grippotyphosa as predominant [13]. Asian studies document Pyrogenes, Javanica, and Bataviae alongside classic serovars [9, 11]. South American surveys reveal high diversity with Copenhageni, Canicola, and Pomona circulating in urban and rural settings [7, 15].

8.2 Urbanization and Climate Change Impacts

Urban expansion creates interfaces between domestic dogs, peri-urban wildlife (raccoons, opossums, rodents), and human populations. Increased rainfall intensity and flooding events amplify environmental contamination and exposure risk. A scoping review of meteorological drivers confirmed positive associations between precipitation, temperature anomalies, and leptospirosis incidence across multiple continents [2].

8.3 Wildlife Reservoirs

Maintenance hosts vary by region: rodents (rats, mice) for Icterohaemorrhagiae/Copenhageni; raccoons and skunks for Grippotyphosa; cattle and pigs for Pomona/Hardjo; hedgehogs for Bratislava. Spillover to dogs occurs at wildlife-domestic interfaces. Genomic studies confirm shared strains between sympatric wildlife and canine populations [10, 11].

9. Future Directions

9.1 Vaccine Development

Subunit vaccines targeting conserved virulence proteins (LipL32, LigA, Loa22) aim to provide cross-protective immunity independent of LPS serovar diversity. Recombinant protein, viral vector, and mRNA platforms are under investigation. Challenge studies in murine models demonstrate partial protection; canine efficacy trials are needed.

9.2 Diagnostic Innovation

Multiplex PCR panels detecting Leptospira alongside other AKI/hepatitis etiologies (CAV-1, Babesia, Anaplasma, toxins) will streamline diagnostic workflows. CRISPR-based detection (SHERLOCK, DETECTR) offers field-deployable molecular diagnostics with attomolar sensitivity. Integration of host transcriptomic signatures may differentiate active infection from serological memory.

9.3 Computational Epidemiology

Machine learning models incorporating climatic, demographic, land-use, and veterinary diagnostic data predict spatiotemporal risk hotspots. These tools enable proactive vaccination campaigns and public health resource allocation. Integration with genomic surveillance platforms facilitates real-time tracking of strain emergence and spread.

10. Conclusion

Canine leptospirosis remains a significant veterinary and public health challenge requiring multidisciplinary coordination. Advances in molecular diagnostics, genomic epidemiology, and subunit vaccine development promise improved control. However, effective management currently relies on clinical vigilance, appropriate diagnostic test selection and interpretation, rigorous infection control, and clear client communication regarding zoonotic risk. The One Health paradigm, integrating human, animal, and environmental health sectors, provides the essential framework for sustainable leptospirosis mitigation.

References

[1] Bringold C, Schweighauser A, Walther S et al. Serial evaluation of clinical, functional, and structural pulmonary changes in 10 dogs with leptospirosis. J Vet Intern Med. 2026.